Evaluation of Satisfaction Regarding Patient's Management of Ocular Surface Diseases (ESPOIR)
Multicentric study, open label, uncontrolled phase IV in 30 patients with meibomian glands dysfunction .
Its objective is to Collect information from patients and ophthalmologists specialized in ocular surface and eyelids to anticipate how Blephasteam ® can be optimized.
This study involves 2 visits, visit of Inclusion, J0, then end of study visit, D21.
Between the two visits patients will be treated with Blephasteam ® for 21 days (up to two uses per day) and complete a questionnaire every two days during the first week and then once a week the next two weeks.
|Study Design:||Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|Official Title:||Phase IV Multicentric Study, 30 Patients Suffering of Meibomian Glands Dysfunction.|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01091311
|HÃ´pital Gabriel Montpied|
|Clermont-Ferrand, France, 63003|
|C.H.N.O des XV-XX|
|Paris, France, 75012|
|Hôpital Bichat - Claude Bernard|
|Paris, France, 75018|
|Principal Investigator:||Christophe Baudouin, Professor||Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts|
|Principal Investigator:||Frédéric Chiambaretta, Professor||Centre Hospitalier Universitaire de Clermont Ferrand|
|Principal Investigator:||Serge Doan, Doctor||Hopital Bichat|